Drugs / OS2966
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04608812 | Mar 2021 → Feb 2023 | anaplastic astrocytoma, glioblastoma | OncoSynergy, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OS2966 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04608812 ↗ |
| Modality | Monoclonal antibody | “OS2966 is an anti-CD29 (Beta1 Integrin) monoclonal antibody (mAb)” NCT04608812 ↗ |
| Route | Other | “participants will receive a single intratumoral infusion of OS2966 directly to the contrast-enhancing bulk tumor by CED” NCT04608812 ↗ |